title: The efficacy of ustekinumab in psoriasis.
abstract: Psoriasis is an immune-mediated cutaneous disease affecting 2% of the worldwide population. While topical therapy, phototherapy, oral systemic therapy, and biologic agents have been used, the treatment of psoriasis still remains a challenge. Ustekinumab is a biologic therapy that provides a novel avenue for management by blocking interleukin-12/23. The purpose of this article is to review the mechanism of action of ustekinumab and its efficacy in psoriatic patients. The use of ustekinumab in other immune-mediated diseases is also discussed. It is our goal to provide dermatologists with the knowledge to enable them to incorporate ustekinumab into their practice.
authors.affiliation: Universidad Nacional de Córdoba, Córdoba, Argentina.
authors.forename: Shannon
authors.initials: S
authors.lastname: Famenini
authors.forename: Jashin J
authors.initials: JJ
authors.lastname: Wu
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007154:Immune System Diseases / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D018664:Interleukin-12 / Q000037:antagonists & inhibitors; D053759:Interleukin-23 / Q000037:antagonists & inhibitors; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D000069549:Ustekinumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D053759:Interleukin-23; D018664:Interleukin-12; D000069549:Ustekinumab